Experts ’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach
ConclusionsThe algorithm presented intends to simplify treatment of AD in China and guide clinical decision-making. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - March 21, 2022 Category: Dermatology Source Type: research
Topical treatment of Eczematous External Otitis involving the ear canal: Long term results of a trial comparing Pimecrolimus 1% Vs Clobetasone Butyrate 0.05
J Laryngol Otol. 2022 Jan 7:1-14. doi: 10.1017/S002221512100445X. Online ahead of print.NO ABSTRACTPMID:34991759 | DOI:10.1017/S002221512100445X (Source: Journal of Laryngology and Otology)
Source: Journal of Laryngology and Otology - January 7, 2022 Category: ENT & OMF Authors: Zsofia Nemeth Emanuele Verga Roberto Verdolini Source Type: research
Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)
(Source: Clinical Epidemiology)
Source: Clinical Epidemiology - December 29, 2021 Category: Epidemiology Tags: Clinical Epidemiology Source Type: research
Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research
